Abstract 1565
Background
Metabolic tumor volume(MTV) measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography(FDG PET/CT) was correlated with prognosis in various cancers. The aim of this study was to investigate the prognostic value of MTV in metastatic breast cancer (MBC).
Methods
We retrospectively reviewed 172 patients who underwent FDG PET/CT at diagnosis of MBC at a single center. MTV for the whole body tumor lesions were measured by FDG PET/CT. The prognostic significance of MTV and other clinicopathological variables for progression free survival (PFS) to the first line palliative treatment(1L-PFS) was assessed by Kaplan-Meier method and Cox proportional hazards regression analysis.
Results
Median age was 45 years (range 27-71). 76 patients had hormone receptor-positive(HR+)/human epidermal receptor-2 negative(HER2-) disease, 55 patients had HER2+ and 41 patients had triple negative breast cancer(TNBC). In the univariate analysis, TNBC subtype and higher MTV was associated with worse 1L-PFS. On multivariate analysis adjusted for age, presence of visceral metastases, and liver involvement, indepent predictive factors associated with decreased 1L-PFS were TNBC (HR 2.724 versus HR+/HER2 subtype, p = 0.002) and MTV (HR 1.165 with doubling of MTV, p = 0.001).
Conclusions
MTV, a volumetric parameter of FDG PET/CT, is an important independent prognostic factor for PFS to the first line palliative treatment, irrespective of tumor subtype, in patients with MBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Y.H. Park: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Research grant / Funding (self): Eisai; Advisory / Consultancy, Research grant / Funding (self): Novartis; Research grant / Funding (self): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
4906 - Tumor-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A restrospective study
Presenter: Sara Giovannoni
Session: Poster Display session 2
Resources:
Abstract
3919 - Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer.
Presenter: Periklis Foukas
Session: Poster Display session 2
Resources:
Abstract
5139 - Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: a MITO24 retrospective study
Presenter: Alberto Farolfi
Session: Poster Display session 2
Resources:
Abstract
4212 - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)
Presenter: Marc Cucurull Salamero
Session: Poster Display session 2
Resources:
Abstract
5123 - TP53 Hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer
Presenter: Marica Garziera
Session: Poster Display session 2
Resources:
Abstract
3795 - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Presenter: Dominique Berton-Rigaud
Session: Poster Display session 2
Resources:
Abstract
2359 - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
Presenter: Alexandra Tyulyandina
Session: Poster Display session 2
Resources:
Abstract
3619 - Baseline IPI (Immune Prognostic Index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI).
Presenter: Felix Blanc-Durand
Session: Poster Display session 2
Resources:
Abstract
3474 - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive inmmunotherapy in ovarian cancer
Presenter: Diego Salas-Benito
Session: Poster Display session 2
Resources:
Abstract
5134 - Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: a pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials).
Presenter: OLIVIER COLOMBAN
Session: Poster Display session 2
Resources:
Abstract